Details for New Drug Application (NDA): 210315
✉ Email this page to a colleague
NDA 210315 describes BACLOFEN, which is a drug marketed by Amneal, Heritage, Maia Pharms Inc, Mylan Labs Ltd, Rubicon, Ani Pharms, Andas 5 Holding, Appco, Aurobindo Pharma Ltd, Beximco Pharms Usa, Endo Operations, Eywa, Graviti Pharms, Impax, Ivax Sub Teva Pharms, Lannett Co Inc, Mankind Pharma, Micro Labs, Northstar Hlthcare, Norvium Bioscience, Oxford Pharms, Rising, Sun Pharm Inds Inc, Teva, Unichem, Upsher Smith Labs, Usl Pharma, Watson Labs, and Zydus Lifesciences, and is included in forty-one NDAs. It is available from fifty-four suppliers. Additional details are available on the BACLOFEN profile page.
The generic ingredient in BACLOFEN is baclofen. There are twenty-one drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the baclofen profile page.
The generic ingredient in BACLOFEN is baclofen. There are twenty-one drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the baclofen profile page.
Summary for 210315
| Tradename: | BACLOFEN |
| Applicant: | Maia Pharms Inc |
| Ingredient: | baclofen |
| Patents: | 0 |
Pharmacology for NDA: 210315
| Mechanism of Action | GABA A Agonists GABA B Agonists |
Medical Subject Heading (MeSH) Categories for 210315
Suppliers and Packaging for NDA: 210315
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BACLOFEN | baclofen | INJECTABLE;INTRATHECAL | 210315 | ANDA | Sagent Pharmaceuticals | 25021-680 | 25021-680-20 | 1 VIAL in 1 CARTON (25021-680-20) / 20 mL in 1 VIAL |
| BACLOFEN | baclofen | INJECTABLE;INTRATHECAL | 210315 | ANDA | MAlA Pharmaceuticals, Inc. | 70511-123 | 70511-123-20 | 1 VIAL, GLASS in 1 CARTON (70511-123-20) / 20 mL in 1 VIAL, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRATHECAL | Strength | 1MG/ML | ||||
| Approval Date: | Jul 30, 2019 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
